Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Wake Forest University Health Sciences
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Primary diagnosis of pancreatic ductal adenocarcinoma (PDAC) confined to the head of the pancreas classified as T1-T3 with one or more of the following high-risk clinical features:
* Carbohydrate antigen (CA) 19-9 greater than 1,000 U/mL with a normal bilirubin;
* Vascular involvement; and/or
* Suspicious regional lymphadenopathy
Intention to undergo open pancreaticoduodenectomy (standard Whipple or pylorus-preserving pancreaticoduodenectomy) as treatment for PDAC
Adequate clinical condition to undergo preoperative (neoadjuvant) hyperthermic intraperitoneal chemotherapy
Adequate clinical condition to undergo perioperative systemic chemotherapy
White blood cell count of at least 3000/mL
Platelet count of at least 100,000/mL
Normal creatinine (\< 2 mg/dL) or creatinine clearance of at least 50 mL/min
Willing and able to give informed consent
You may not be if
Evidence of locoregional spread (carcinomatosis of peritoneal surfaces, mesenteric arteries, or body/tail of pancreas) or distant (liver, lung, or other) metastases (histological, CT, or MRI confirmation)
Non-curative intent of treatment (≥R2 resection)
Body mass index (BMI) \> 35
Previous history of pancreatic resections for tumors in the body and/or tail of the pancreas, distal cholangiocarcinoma, duodenal carcinoma, neuroendocrine tumors, cyst-adenocarcinoma, or solid and papillary tumors.
Unstable or uncompensated respiratory or cardiac disease
Severe hepatic or renal dysfunction
Bleeding diathesis or coagulopathy
Pregnant or nursing women
Clareo Health | HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma
